Tax exemption for regulatory authority income applies retrospectively, subject to non-commercial activity, unchanged income sources, and return filing...
Dispute Resolution Panel objections must reach both prescribed forums; otherwise assessment may proceed and statutory appeal remains the proper remedy...
Political contribution deductions require recipient party compliance with contribution-reporting conditions; banking-channel donations alone do not qu...
Aggregation under TNMM prevents selective testing of intra-group services without comparable uncontrolled transactions, while appellate additional cla...
Protective assessment cannot duplicate identical receipts under competing characterisations; remote services did not establish a taxable permanent est...
Page of 4792
Press 'Enter' after typing page number.
461 to 480 of 95833 Results
❮
❯
❯❯
0 / 200
Expand Note
Add to Folder
No Folders have been created
+
Are you sure you want to delete "My most important" ?
Active Pharmaceutical Ingredients and bulk drugs qualify as "All Drugs and medicines" under the specific IGST rate entry where they retain their statutory identity as drugs under the Drugs and Cosmetics Act, 1940. Their import for formulation manufacture, testing, analysis, clinical research, clinical trials, bioavailability studies or bioequivalence studies does not alter that character. The description-based entry extends to goods under Chapter 30 or any other chapter, including APIs tariff-classifiable under Chapters 28 or 29. As the specific drugs entry prevails over general chemical entries, eligible APIs attract IGST at 5%, subject to exclusion where covered by the specified nil-rated entry.
Active Pharmaceutical Ingredients and bulk drugs qualify as "All Drugs and medicines" under the specific IGST rate entry where they retain their statutory identity as drugs under the Drugs and Cosmetics Act, 1940. Their import for formulation manufacture, testing, analysis, clinical research, clinical trials, bioavailability studies or bioequivalence studies does not alter that character. The description-based entry extends to goods under Chapter 30 or any other chapter, including APIs tariff-classifiable under Chapters 28 or 29. As the specific drugs entry prevails over general chemical entries, eligible APIs attract IGST at 5%, subject to exclusion where covered by the specified nil-rated entry.
Note: It is a system-generated summary and is for quick reference only.